2
|
Lei K, Georgiou EX, Chen L, Yulia A, Sooranna SR, Brosens JJ, Bennett PR, Johnson MR. Progesterone and the Repression of Myometrial Inflammation: The Roles of MKP-1 and the AP-1 System. Mol Endocrinol 2015; 29:1454-67. [PMID: 26280733 DOI: 10.1210/me.2015-1122] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Progesterone (P4) maintains uterine quiescence during pregnancy and its functional withdrawal is associated with increased prostaglandin synthesis and the onset of labor. In primary human myometrial cells, the glucocorticoid receptor (GR) rather than the P4 receptor mediates P4 antagonism of IL-1β-induced cyclooxygenase-2 (COX-2) expression, the rate-limiting enzyme in prostaglandin synthesis. We now report that P4 also acts via GR to induce MAPK phosphatase (MKP)-1 and knockdown of MKP-1 impairs the ability of P4 to repress IL-1β-dependent COX-2 induction. Microarray analysis revealed that P4 repressed preferentially activator protein-1-responsive genes in response to IL-1β. Consistent with these observations, we found that the ability of P4 to reduce c-Jun activation was lost upon GR as well as MKP-1 knockdown. Interestingly, c-Jun levels in human myometrial cells declined upon GR and MKP-1 knockdown, which suggests the presence of an activator protein-1 feedback loop. This is supported by our observation that c-Jun levels declined after an initial rise in primary myometrial cells treated with phorbol 12-myrisatate 13-acetate, a potent activator of c-Jun N-terminal kinase. Finally, we show that MKP-1 is an intermediate in P4-mediated repression of some but not all IL-1β-responsive genes. For example, P4 repression of IL11 and IRAK3 was maintained upon MKP-1 knockdown. Taken together, the data show that P4 acts via GR to drive MKP-1 expression, which in turn inhibits IL-1β-dependent c-Jun activation and COX-2 expression.
Collapse
Affiliation(s)
- K Lei
- Imperial College Parturition Research Group (K.L., E.X.G., L.C., A.Y., S.R.S., M.R.J.), Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom; Institute of Reproductive and Developmental Biology (KL.,. E.X.G., A.Y., S.R.S., P.R.B., M.R.J.), Hammersmith Hospital Campus, London W12 0NN, United Kingdom; Obstetrics Department (L.C.), First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, People's Republic of China; and Reproductive Health (J.J.B.), University of Warwick, Coventry CV4 7AL, United Kingdom
| | - E X Georgiou
- Imperial College Parturition Research Group (K.L., E.X.G., L.C., A.Y., S.R.S., M.R.J.), Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom; Institute of Reproductive and Developmental Biology (KL.,. E.X.G., A.Y., S.R.S., P.R.B., M.R.J.), Hammersmith Hospital Campus, London W12 0NN, United Kingdom; Obstetrics Department (L.C.), First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, People's Republic of China; and Reproductive Health (J.J.B.), University of Warwick, Coventry CV4 7AL, United Kingdom
| | - L Chen
- Imperial College Parturition Research Group (K.L., E.X.G., L.C., A.Y., S.R.S., M.R.J.), Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom; Institute of Reproductive and Developmental Biology (KL.,. E.X.G., A.Y., S.R.S., P.R.B., M.R.J.), Hammersmith Hospital Campus, London W12 0NN, United Kingdom; Obstetrics Department (L.C.), First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, People's Republic of China; and Reproductive Health (J.J.B.), University of Warwick, Coventry CV4 7AL, United Kingdom
| | - A Yulia
- Imperial College Parturition Research Group (K.L., E.X.G., L.C., A.Y., S.R.S., M.R.J.), Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom; Institute of Reproductive and Developmental Biology (KL.,. E.X.G., A.Y., S.R.S., P.R.B., M.R.J.), Hammersmith Hospital Campus, London W12 0NN, United Kingdom; Obstetrics Department (L.C.), First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, People's Republic of China; and Reproductive Health (J.J.B.), University of Warwick, Coventry CV4 7AL, United Kingdom
| | - S R Sooranna
- Imperial College Parturition Research Group (K.L., E.X.G., L.C., A.Y., S.R.S., M.R.J.), Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom; Institute of Reproductive and Developmental Biology (KL.,. E.X.G., A.Y., S.R.S., P.R.B., M.R.J.), Hammersmith Hospital Campus, London W12 0NN, United Kingdom; Obstetrics Department (L.C.), First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, People's Republic of China; and Reproductive Health (J.J.B.), University of Warwick, Coventry CV4 7AL, United Kingdom
| | - J J Brosens
- Imperial College Parturition Research Group (K.L., E.X.G., L.C., A.Y., S.R.S., M.R.J.), Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom; Institute of Reproductive and Developmental Biology (KL.,. E.X.G., A.Y., S.R.S., P.R.B., M.R.J.), Hammersmith Hospital Campus, London W12 0NN, United Kingdom; Obstetrics Department (L.C.), First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, People's Republic of China; and Reproductive Health (J.J.B.), University of Warwick, Coventry CV4 7AL, United Kingdom
| | - P R Bennett
- Imperial College Parturition Research Group (K.L., E.X.G., L.C., A.Y., S.R.S., M.R.J.), Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom; Institute of Reproductive and Developmental Biology (KL.,. E.X.G., A.Y., S.R.S., P.R.B., M.R.J.), Hammersmith Hospital Campus, London W12 0NN, United Kingdom; Obstetrics Department (L.C.), First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, People's Republic of China; and Reproductive Health (J.J.B.), University of Warwick, Coventry CV4 7AL, United Kingdom
| | - M R Johnson
- Imperial College Parturition Research Group (K.L., E.X.G., L.C., A.Y., S.R.S., M.R.J.), Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom; Institute of Reproductive and Developmental Biology (KL.,. E.X.G., A.Y., S.R.S., P.R.B., M.R.J.), Hammersmith Hospital Campus, London W12 0NN, United Kingdom; Obstetrics Department (L.C.), First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, People's Republic of China; and Reproductive Health (J.J.B.), University of Warwick, Coventry CV4 7AL, United Kingdom
| |
Collapse
|
6
|
Hanczko R, Fernandez DR, Doherty E, Qian Y, Vas G, Niland B, Telarico T, Garba A, Banerjee S, Middleton FA, Barrett D, Barcza M, Banki K, Landas SK, Perl A. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest 2009; 119:1546-57. [PMID: 19436114 DOI: 10.1172/jci35722] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2008] [Accepted: 03/11/2009] [Indexed: 01/12/2023] Open
Abstract
Although oxidative stress has been implicated in acute acetaminophen-induced liver failure and in chronic liver cirrhosis and hepatocellular carcinoma (HCC), no common underlying metabolic pathway has been identified. Recent case reports suggest a link between the pentose phosphate pathway (PPP) enzyme transaldolase (TAL; encoded by TALDO1) and liver failure in children. Here, we show that Taldo1-/- and Taldo1+/- mice spontaneously developed HCC, and Taldo1-/- mice had increased susceptibility to acetaminophen-induced liver failure. Oxidative stress in Taldo1-/- livers was characterized by the accumulation of sedoheptulose 7-phosphate, failure to recycle ribose 5-phosphate for the oxidative PPP, depleted NADPH and glutathione levels, and increased production of lipid hydroperoxides. Furthermore, we found evidence of hepatic mitochondrial dysfunction, as indicated by loss of transmembrane potential, diminished mitochondrial mass, and reduced ATP/ADP ratio. Reduced beta-catenin phosphorylation and enhanced c-Jun expression in Taldo1-/- livers reflected adaptation to oxidative stress. Taldo1-/- hepatocytes were resistant to CD95/Fas-mediated apoptosis in vitro and in vivo. Remarkably, lifelong administration of the potent antioxidant N-acetylcysteine (NAC) prevented acetaminophen-induced liver failure, restored Fas-dependent hepatocyte apoptosis, and blocked hepatocarcinogenesis in Taldo1-/- mice. These data reveal a protective role for the TAL-mediated branch of the PPP against hepatocarcinogenesis and identify NAC as a promising treatment for liver disease in TAL deficiency.
Collapse
Affiliation(s)
- Robert Hanczko
- Department of Medicine, College of Medicine, State University of New York, Syracuse, New York 13210, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 2009; 60:261-310. [PMID: 18922965 DOI: 10.1124/pr.107.00106] [Citation(s) in RCA: 438] [Impact Index Per Article: 29.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Mitogen-activated protein kinase dual-specificity phosphatase-1 (also called MKP-1, DUSP1, ERP, CL100, HVH1, PTPN10, and 3CH134) is a member of the threonine-tyrosine dual-specificity phosphatases, one of more than 100 protein tyrosine phosphatases. It was first identified approximately 20 years ago, and since that time extensive investigations into both mkp-1 mRNA and protein regulation and function in different cells, tissues, and organs have been conducted. However, no general review on the topic of MKP-1 exists. As the subject matter pertaining to MKP-1 encompasses many branches of the biomedical field, we focus on the role of this protein in cancer development and progression, highlighting the potential role of the mitogen-activated protein kinase (MAPK) family. Section II of this article elucidates the MAPK family cross-talk. Section III reviews the structure of the mkp-1 encoding gene, and the known mechanisms regulating the expression and activity of the protein. Section IV is an overview of the MAPK-specific dual-specificity phosphatases and their role in cancer. In sections V and VI, mkp-1 mRNA and protein are examined in relation to cancer biology, therapeutics, and clinical studies, including a discussion of the potential role of the MAPK family. We conclude by proposing an integrated scheme for MKP-1 and MAPK in cancer.
Collapse
Affiliation(s)
- Tarek Boutros
- Department of Surgery, Royal Victoria Hospital, McGill University, 687 Pine Ave. W., Montreal, QC H3A1A1, Canada.
| | | | | |
Collapse
|